Marc Odrich
Nessuna posizione attualmente
Patrimonio netto: 2 M $ in data 31/05/2024
Profilo
Marc Odrich is currently the Chief Medical Officer & Director at TearSolutions, Inc., the Director at CXL Ophthalmics LLC, the Chief Medical Officer at LENZ Therapeutics, Inc., and an Associate Professor at the University of Virginia.
He previously worked as the Medical Director at VISX, Inc. Dr. Odrich holds a doctorate degree from Columbia University College of Physicians & Surgeons.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
0.39% | 21/03/2024 | 99 599 ( 0.39% ) | 2 M $ | 31/05/2024 |
Posizioni attive di Marc Odrich
| Società | Posizione | Inizio |
|---|---|---|
TearSolutions, Inc.
 TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Corporate Officer/Principal | - |
CXL Ophthalmics LLC
 CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Direttore/Membro del Consiglio | - |
| University of Virginia | Corporate Officer/Principal | - |
Precedenti posizioni note di Marc Odrich
| Società | Posizione | Fine |
|---|---|---|
| VISX, Inc. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Marc Odrich
| Columbia University College of Physicians & Surgeons | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
TearSolutions, Inc.
TearSolutions, Inc. BiotechnologyHealth Technology TearSolutions, Inc. develops natural tear generation therapy for dry eyes. The firm's platform technology focuses on the tear protein 'lacritin'? and the proprietary drug 'Lacripep'?. The company was founded by Mark B. Logan, and Gordon W. Laurie in 2013 and is headquartered in Charlottesville, VA. | Health Technology |
| VISX, Inc. | |
CXL Ophthalmics LLC
CXL Ophthalmics LLC Medical/Nursing ServicesHealth Services CXL Ophthalmics LLC develops a treatment for eyecare. The company is based in Encinitas, CA. The CEO of the company is Michael D. Webb. | Health Services |
- Borsa valori
- Insiders
- Marc Odrich
